Evidence map›Paper›PMID 42080552›Full record

ReviewJournal of virology2026

Comparison of Ebola virus infection routes and resulting disease in animal models.

B Ryder Gathright, Andrea Marzi

Abstract readReviewComparative Study
In one paragraph

Review in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

B Ryder GathrightLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, , Hamilton, Montana, USA.
Andrea MarziLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, , Hamilton, Montana, USA.ORCID 0000-0003-0186-9587

Funding

Immunobiology, molecular virology and countermeasures of highly pathogenic virusesZIAAI001254 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MARZI, ANDREA · 2020 to 2025
$16.6M
NIH HHS ZIA AI001254
6 · The paper itself

Abstract

Ebola virus disease (EVD) is a highly pathogenic and lethal disease caused by Ebola virus (EBOV). Endemic to Sub-Saharan Africa, EBOV has been causing global health concerns during infrequent EVD outbreaks since 1976, particularly during the 2013 -2016 epidemic in West Africa. Spread by contact of contaminated bodily fluids with mucous membranes or breaks in the skin, EBOV yields an incredibly high mortality rate and, as a result, has been designated a priority pathogen and a select agent to be studied exclusively in maximum containment laboratories. EBOV has historically been studied in animal models that accurately recapitulate disease progression, symptoms, and outcomes as seen in humans via more artificial infection routes such as intramuscular (IM) and intraperitoneal (IP) inoculation. There has recently been a concerted effort to characterize disease in animal models with mucosal inoculation routes with the goal to more accurately replicate human infection and development of EVD. This review aims to summarize and characterize the different inoculation routes used in the various animal models applied in EBOV research. We also outline the differences in disease progression between "artificial" and mucosal infection routes, comparing them to the course of EVD as seen in humans to highlight similarities and differences.

Indexed as

Disease Models, AnimalEbolavirusHemorrhagic Fever, EbolaAnimalsHumansInjections, Intramuscularaerosol exposurefilovirusintramuscular infectionintranasal infectionmucosal infectionpathogenesis

Identifiers

PMID42080552
PMCPMC13296617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.